Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07929480
PHASE1/PHASE2

A Phase 1/2a Clinical Study of KL002 in Treatment of Parkinson's Disease

Sponsor: Kanglin Biotechnology (Hangzhou) Co., Ltd.

View on ClinicalTrials.gov

Summary

To assess the safety and tolerability of single doses of KL002 over 78 weeks in subjects with Parkinson's disease。

Official title: A Phase 1/2a, Open-Label, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of KL002, an AAV9 Gene Therapy, in Subjects With Parkinson's Disease

Key Details

Gender

All

Age Range

40 Years - 75 Years

Study Type

INTERVENTIONAL

Enrollment

12

Start Date

2026-12

Completion Date

2029-10

Last Updated

2026-11-10

Healthy Volunteers

No

Interventions

GENETIC

Injecting KL002 into the bilateral putamen

KL002 is a recombinant adeno-associated virus (rAAV9) vector carrying TH, GCH1, and AADC genes

Locations (1)

Houston Methodist Hospital

Houston, Texas, United States